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Abstract
With increasing pressures to reduce or eliminate the use of antimicrobials for growth promotion purposes in production
animals, there is a growing need to better understand the effects elicited by these agents in order to identify alternative
approaches that might be used to maintain animal health. Antibiotic usage at subtherapeutic levels is postulated to confer
a number of modulations in the microbes within the gut that ultimately result in growth promotion and reduced
occurrence of disease. This study examined the effects of the coccidiostat monensin and the growth promoters
virginiamycin and tylosin on the broiler chicken cecal microbiome and metagenome. Using a longitudinal design, cecal
contents of commercial chickens were extracted and examined using 16S rRNA and total DNA shotgun metagenomic
pyrosequencing. A number of genus-level enrichments and depletions were observed in response to monensin alone, or
monensin in combination with virginiamycin or tylosin. Of note, monensin effects included depletions of Roseburia,
Lactobacillus and Enterococcus, and enrichments in Coprococcus and Anaerofilum. The most notable effect observed in the
monensin/virginiamycin and monensin/tylosin treatments, but not in the monensin-alone treatments, was enrichments in
Escherichia coli. Analysis of the metagenomic dataset identified enrichments in transport system genes, type I fimbrial
genes, and type IV conjugative secretion system genes. No significant differences were observed with regard to
antimicrobial resistance gene counts. Overall, this study provides a more comprehensive glimpse of the chicken cecum
microbial community, the modulations of this community in response to growth promoters, and targets for future efforts to
mimic these effects using alternative approaches.
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Introduction
For more than 50 years, antibiotic growth promoters (AGPs)
have been used in agricultural animal production in the United
States and other countries as a means to increase production
through maintained animal health and improved feed efficiency.
The ionophore monensin has been used by the broiler industries in
the United States for over forty years to control coccidiosis in
poultry [1]. Monensin has broad anticoccidial activity [2] and a
mode of action targeted at the Eimeria parasite. In the United
States broiler chicken and turkey industries, AGPs and monensin
are commonly combined in feed at low levels. Despite the
successes of such use in poultry, the underlying mechanisms
responsible for these effects are not completely understood. It is
assumed that modulation of the gut flora by constant low level
presence of an antibiotic plays a role in the benefits conferred to
the host [3].
The benefits of AGP use in production animals are often argued
to be outweighed by their negative effects. For example, the use of
AGPs has been associated with the emergence of pathogens
resistant to fluoroquinolones, vancomycin, and third- and fourth-
generation cephalosporins, among others [4], which has already
led to a ban on AGP use in feed in the European Union [5]. Until
recently, there has been little regulatory activity regarding AGPs in
the United States; however, in 2005 the U.S. Food and Drug
Administration banned the use of enrofloxacin in poultry due to
an increase in fluoroquinolone-resistant Campylobacter, a trend that
paralleled the increased use of the drug in the poultry industry [6].
Both political and consumer pressures are prompting a reduction
in the use of AGPs in production animals, necessitating the
identification of alternative approaches that will exhibit similar
benefits to animals. Tylosin and virginiamycin are two antibiotics
of interest because both are used in the U.S. poultry industry and
have analogs in use (erythromycin and quinupristin-dalfopristin,
respectively) for therapy against human pathogens. Erythromycin
resistance in Campylobacter jejuni has been reported as high as 56.1%
in broilers treated with subjected to subtherapeutic tylosin
administration [7]. In addition, Kieke et al. reported 56%
resistance in Enterococci faecium isolated from chicken and an
association between poultry consumption and inducible quinu-
pristin-dalfopristin resistance [8]. Because of these findings, efforts
are now underway in the U.S. by many poultry producers to phase
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underscoring the need to better understand their impacts on gut
flora.
A number of previous studies on poultry bacterial populations
have relied on cultivation and enumeration of bacterial species [9];
more recently, PCR-based culture-independent methods have
been employed in an effort to overcome the limitations and biases
associated with culture-based techniques [10]. The most com-
monly used molecular methods rely on amplification of the 16S
rRNA, such as denaturing gradient gel electrophoresis (DGGE) of
the PCR-amplified 16S rRNA genes [11,12], use of species-
specific primers [13], or sequencing of randomly selected 16S
rRNA clones [14]. Amplification of one or more hypervariable
regions of the 16S rRNA region followed by parallel tag
pyrosequencing is now commonly employed to analyze many
different bacterial populations [15,16]. In this study, we used
pyrosequencing of the V3 hypervariable region and shotgun
metagenomic sequencing to analyze the effects of subtherapeutic
levels of two antimicrobials, virginiamycin and tylosin, and the
anticoccidial monensin, on bacterial populations in the chicken
cecum.
Materials and Methods
Sample Collection
All animal experiments were performed in accordance with the
Institutional Animal Care and Use Committee at the University of
Minnesota under protocol number 0807A39862. Two trials were
performed using commercial day-of-hatch Ross x Ross chickens
(n=160) randomly separated into 4 groups of 40 birds. The
groups were housed in separate pens in the same building in the
Research Animal Facility at the University of Minnesota. The four
groups were fed the same control diet without antibiotics until
seven days of age, when three groups were switched to a diet
containing subtherapeutic levels of monensin sodium (110 g/ton),
or monensin sodium (110 g/ton) with virginiamycin (15 g/ton) or
tylosin phosphate (20 g/ton), in accordance with FDA guidelines
(http://www.fda.gov/); the fourth group remained on the control
diet. At day 0 pre-treatment, and days 7, 14, and 35 post-diet
alteration, 10 chickens were randomly selected from each group
and humanely euthanized. Cecal contents were aseptically
collected from each bird and immediately stored at 280uC and
promptly processed.
DNA Extraction
Cecal samples from the chickens were pooled together
according to group and time point. DNA was extracted from
pooled samples using a bead-beating procedure. Briefly, 0.25 g of
pooled cecal content were suspended in 1 ml lysis buffer
(500 mM NaCl, 50 mM Tris-Cl, pH 8.0, 50 mM EDTA, 4 %
SDS) with glass beads, including 0.3 g of 0.1 mm size and 0.1 g
of 0.5 mm size (Biospec Products, Bartlesville, OK), and
homogenized on a bead-beater for 3 min at full speed. The
samples were then heated at 70uC for 15 min, followed by
centrifugation to separate the DNA from the bacterial cellular
debris. This process was repeated with a second 300 ul aliquot of
lysis buffer. The samples were then subjected to 10 M v/v
ammonium acetate precipitation, followed by isopropanol
precipitation and a 70% ethanol wash and resuspended in
100 ul 16 Tris-EDTA (Fisher Scientific, Fair Lawn, NJ). The
samples were treated with DNase-free RNase (Roche, Basel,
Switzerland) for 15 minutes at 37uC, and then processed through
the QIAmpH DNA Stool Mini Kit (Qiagen, Valencia, CA)
according to manufacturer’s directions with some modifications.
Samples were measured on a Nanodrop ND-1000 spectropho-
tometer (Thermo Scientific) to assess DNA quantity.
16S rRNA Amplification and 454 Sequencing
The V3 hypervariable region of the 16S rRNA gene was
amplified in a 50 ml reaction containing 16 PCR buffer
(containing 1.8 mM MgCl2), 0.2 mM each dNTP (Promega,
Madison, WI), 0.4 mM each primer (Integrated DNA Technolo-
gies, Coralville, IA), 2.5 U FastStart High Fidelity Taq Polymerase
(Roche), and 50 ng DNA template. The primers used were 59-
CCTACGGGAGGCAGCAG-39 with adapter A (forward primer)
and 59-ATTACCGCGGCTGCTGG-39 with adapter B (reverse
primer), and sample-specific sequence barcodes designed by
Roche (Technical Bulletin 013-2009) [17,18]. The PCR condi-
tions used were 95uC for 2 min; 20 cycles of 95uC for 30 sec, 60uC
for 30 sec and 72uC for 30 sec; followed by 72uC for 7 min. Two
amplification reactions were run for each sample and pooled
together. The PCR product (approximately 230 bp) was excised
from a 1.5% agarose gel stained with ethidium bromide and
purification was performed using the QIAquick Gel Extraction Kit
(Qiagen). DNA quality and concentration were assessed on a
Bioanalyzer 2100 (Agilent, Palo Alto, CA) using a DNA 1000 lab
chip. Barcoded samples were combined equal concentrations of
5 ng/ml and divided into 2 runs; pyrosequencing was carried out
by the BioMedical Genomics Center at the University of
Minnesota using GS FLX technology (Roche).
Metagenomic Sequencing
Total DNA from pooled samples from the day 14 and day 35
post-treatment timepoints were subjected to shotgun metagenomic
sequencing using GS-FLX sequencing with Titanium chemistry.
Eight pooled samples (D14C, D14M, D14V, D14T, D35C, D35M,
D35V, and D35T) were barcoded and sequenced on one full plate.
The amplicon and metagenome reads used in this paper are
publicly available from the SEED platform (http://metagenomics.
anl.gov/).
Data Analysis
Following sequencing, all barcodes were sorted, removed, and
reads were quality assessed. To minimize effects of random
sequencing errors, we eliminated 1) sequences that did not
appropriately match the PCR primer and the barcode at the
beginning of a read, 2) sequence reads with ,50 bases after the
proximal PCR primer if they terminated before reaching the distal
primer, 3) sequences that contained more than one undetermined
nucleotide (N), and 4) sequences with a average phred quality score
of #27. Both the proximal and distal primers were trimmed from
high-quality reads before database searches and similarity
calculations. Then, the 16S rRNA sequences were quality
screened and trimmed to identical beginning and end nucleotides
extending from the end of the V3 universal primers. The RDP
Database was used to assign reads to taxonomic groups with a
bootstrap cut-off of 80% and perform statistical comparisons
between groups [19]. The Mothur package [20] was used in
operational taxonomic unit (OTU)-based analysis including
rarefaction curves, dendrogram, Venn diagrams, and heat maps
with an OTU definition at a similarity cutoff of 95%. Principal
coordinate analysis (PCoA) plots were generated using Fast
Unifrac. Enriched and depleted OTUs were identified using
METASTATS [21]. The OTUs were obtained from Mothur, and
were sorted from most to least abundant OTUs. Sequence
abundance values within each OTU were normalized for
comparisons of V3 OTU abundance between samples. Then,
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was used for hierarchical clustering and visualization [22].
For metagenomic analysis, MG-RAST subsystem analysis was
used to assign reads to functional groups using blastX and to
identify bacterial taxa based upon metagenomic 16S rDNA reads
[23]. MEGAN was used to assign total reads to taxonomic groups
to all reads [24]. JMP was used for hierarchical clustering and
visualization.
Results
In total, 106,810 16S rRNA amplicon sequences were analyzed
(Table 1). These reads were analyzed using two approaches: 1)
classification of reads using the Ribosomal Database Project (RDP;
http://rdp.cme.msu.edu/) [25]; and 2) assignment of reads to
OTUs for analysis in the Mothur package [20].
Taxonomic classification of 16S rRNA reads using RDP
Sequence reads were analyzed on the phylum, class, order,
family, and genus levels using the RDP database with a bootstrap
confidence threshold of 80%. The dominant phylum at each
timepoint was Firmicutes, comprising 75–90% of the samples
throughout the experiment (Fig. 1 and Table S1). Using RDP’s
compare algorithm (Fig. S1), Firmicutes were found to be
significantly depleted (p,0.05) in the day 7 and day 14
monensin/virginiamycin-treated groups and the day 14 monen-
sin/tylosin-treated group, as compared to the control group for
each respective timepoint. These reductions were not observed in
the monensin-only treatment groups. Class distributions were also
analyzed among the post-treatment timepoints (Fig. 2). The
dominant class was Clostridia, followed by Bacilli and Gammaproteo-
bacteria. In response to treatment, monensin alone acted to
significantly reduce Bacilli at all three timepoints, an effect that
was also observed for the monensin/virginiamycin and monensin/
tylosin treatment groups. In contrast, monensin/virginiamycin
and monensin/tylosin acted to increase Gammaproteobacteria at all
three timepoints but this effect was not observed in the monensin-
alone treatment groups (Fig. S1; p,0.05). Among the Firmicutes,
the predominant families were Lachnospiriceae, Ruminococcaceae, and
Incertae Sedis XIV (Fig. 3). A number of Firmicutes families were
significantly decreased by monensin alone, and/or monensin/
AGP treatment, including Erysipelotrichaceae at day 7 post-treatment
in all groups, Lactobacillaceae by monensin alone at all timepoints,
Enterococcaceae at day 14 by all groups, Lachnospiraceae at day 7 by all
groups, and Insertae Sedis XIV by monensin alone at all timepoints
(Fig. S1; p,0.05). On the genus level, there were a number of
Firmicutes genera that were either significantly enriched or depleted
by monensin and/or growth promoter treatment (p,0.05).
Roseburia was significantly depleted at nearly all timepoints by all
treatment types, compared to the control group. In contrast,
Escherichia was significantly enriched at all timepoints in the
virginiamycin- and tylosin-treated groups (Fig. S1).
Comparison of 16S rRNA reads using OTU analysis
The 16S rRNA sequence reads were also binned according to
their sequence similarities with one another, and independent of
any database hits or searches. With an OTU definition at a
similarity cut-off of 95%, a total of 2,304 OTUs were identified
among the 16 different groups examined. There was an overall
increase in the number of OTUs identified per group as the bird
aged (Table 1). This was also reflected by the Chao1, Shannon,
and Simpson analyses of sample richness and diversity, which
suggested that sample richness and diversity increased with the
increasing age of the bird. Rarefaction analysis of the experimental
groups agreed with this, as the slopes of the curves increased with
increasing bird age (Fig. 4). Each of the 2,203 OTUs were
analyzed for significant enrichments or depletions in treatment
groups, as compared to the control groups of the same timepoint,
then OTUs with significant changes (p,0.05) were sorted by
abundance and classified using RDP (Fig. 5 and Table S2). A
number of OTUs were uniformly affected across treatment groups
and/or timepoints. OTUs that were significantly and uniformly
depleted included those classified as Roseburia, Enterococcus,
Lactobacillus, and Blautia. OTUs that were significantly and
Table 1. Number of OTUs per groups and estimators of sequence diversity and richness.
# of Sequences # of OTUs Chao1 (richness) Shannon (diversity) Simpson (diversity:1-D)
Day 0 control
A 4,872 259 430.7 3.2 0.91
Day 7 control 12,076 717 1267.9 4.3 0.96
Day 14 control 6,614 598 997.5 4.5 0.96
Day 35 control 7,023 678 1304.2 4.8 0.97
Day 0 monensin 3,006 105 216.4 2.2 0.73
Day 7 monensin 7,529 415 742.4 3.9 0.95
Day 14 monensin 12,987 783 1280.1 4.5 0.97
Day 35 monensin 1,944 348 556.5 4.9 0.99
Day 0 monensin + virginiamycin 7,504 379 620.6 3.7 0.94
Day 7 monensin + virginiamycin 8,797 538 877.8 4.3 0.96
Day 14 monensin + virginiamycin 7,882 690 1078.8 4.7 0.98
Day 35 monensin + virginiamycin 5,114 570 898.5 5 0.98
Day 0 monensin + tylosin 1,776 109 220.4 2.7 0.82
Day 7 monensin + tylosin 8,716 539 840.9 4.1 0.95
Day 14 monensin + tylosin 5,816 531 885.5 4.6 0.97
Day 35 monensin + tylosin 5,154 605 1056.5 5 0.98
ADay 0 samples were collected prior to the start of treatments. Subsequent days represent days post-treatment start.
doi:10.1371/journal.pone.0027949.t001
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Coprococcus, Lutispora, and Hespellia. There were also OTUs that
were only enriched or depleted in the virginiamycin/tylosin groups
but not the monensin group relative to control groups within the
same timepoints, such as those classified as Fastidiosipila, Escherichia,
and Hespellia.
The OTU composition across groups was further analyzed for
similarities in community structure using the Bray-Curtis index. In
the resulting dendrogram, groups tended to cluster by bird age
(Fig. 6). However, the day 14 control and monensin-treated groups
clustered with all day 7 groups, whereas the day 14 monensin/
virginiamycin and monensin/tylosin treatment groups clustered
with the day 35 groups. A PCoA plot was also generated using all
of the amplicon sequencing reads, and the samples were
predominantly clustered according to bird age although the
treatment groups at later timepoints also clustered separate from
control groups of the same timepoint (Fig. S2). Venn diagrams
were constructed to depict shared and unique OTUs among the
groups examined at each timepoint. At 14 days after the start of
treatment, 192 (18.9%) OTUs were shared among all groups
studied, while 507 (49.9%) were unique to one of the four different
treatment groups (Fig. 7). RDP classification of the unique OTUs
belonging to the monensin/virginiamycin and monensin/tylosin
treatment groups revealed that most of the sequences were
classified within the family Ruminococcaceae, including the genera
Anaerotruncus, Subdoligranulum, and Sedimentibacter, all absent from the
control group.
Changes in cecum microbiome microbial community
structure over time
Two-way hierarchical clustering was also performed to depict
the relationships between OTUs and experimental groups based
upon sequence abundance within each OTU (Fig. 8). Here,
changes in OTU structure based upon bird age were evident, with
certain OTUs present in the cecum of the young birds that
disappeared over time, OTUs that emerged in the cecum of birds
of older ages, and some OTUs that were present throughout the
production lifespan of the chicken. For instance, the most
abundant OTUs with RDP classification as Roseburia, Coprococcus,
Butyricicoccus, Escherichia, and Papillibacter appeared at 14 days of age
(day 7 post-treatment) and persisted through 42 days of age (day
35 post-treatment). Some OTUs with RDP classification as
Lactobacillus, Parasporobacterium, and Ethanoligenens were present prior
to the start of treatments but disappeared at later timepoints. Some
OTUs with RDP classification as Firmicutes, such as the genera
Butyricicoccus, Oscillibacter, Roseburia, and Blautia were consistently
present throughout all timepoints. Furthermore, as the chicken gut
diversified, older birds of all groups acquired OTUs classified as
genera Fastidiospila, Hespellia, Lactobacillus, and Coprococcus.
Chicken cecum metagenome changes in response to
growth promoter treatment
Shotgun metagenome sequencing was performed on samples at
days 14 and 35 post-treatment to identify changes in the metabolic
potential of the cecum microbial population in response to
Figure 1. Bacterial phyla distributions at the three timepoints after the start of treatments, using V3 amplicon sequencing
(n=89,652). For each timepoint, C = control diet, M = monensin treatment, V = monensin/virginiamycin treatment, and T = monensin/tylosin
treatment.
doi:10.1371/journal.pone.0027949.g001
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ments (Table 2). A total of 1,291,219 reads with average lengths
ranging from 234–399 bp were generated spanning the eight
groups and timepoints sequenced. The proportion of bacterial
sequences in this sample was estimated at 94–97% based upon
reads from the metagenomic dataset, with the remainder of these
reads belonging primarily to Archaea and Eukarya (Table 2).
MG-RAST was used to bin the sequences into functional
groups on three different subsystem levels. Pairwise comparisons
were then performed between control versus treatment groups of
the same timepoint, and between monensin alone versus
monensin/AGP treatment groups of the same timepoint. On
the broadest level containing 29 different subsystems, no
significant changes (p,0.05) were observed between any of the
groups examined (Fig. S3). The most prevalent functional groups
to which the sequences were binned included carbohydrate
utilization, clustering-based subsystems (functional coupling
evidence but unknown function), protein metabolism, and amino
acid synthesis (Fig. S4). When analyzed on the most focused
subsystem level containing 773 functional groups, a number of
significant changes (p,0.05) were observed between the control
versus monensin treatment groups, and between the monensin
versus monensin/AGP treatment groups. The most significant
changes observed in the control and/or monensin versus
monensin/AGP treatment comparisons included sequence en-
richments in subsystems containing ‘transporters in models’, type
IV secretion systems, and type I pili (Fig. 9 and Fig. S5). The
‘transporter in models’ group included reads with similarity to a
variety of bacterial species, with predicted proteins such as amino
acid carrier proteins, iron transport system proteins, potassium/
sodium efflux proteins, magnesium transport system proteins,
uncharacterized ABC-type transporter systems, heavy metal and
antimicrobial transport system proteins, and sugar transport
system proteins. The type IV secretion system subgroup included
genes from IncF and IncI1 plasmids with predicted protein hits to
the conjugative transfer systems of these plasmids. The type I pili
group included reads mostly with similarity to E. coli, and
included predicted proteins matching their type I fimbrial
components. Analysis of all functional classes of antimicrobial
resistance genes revealed no significant differences between the
control and treatment groups in the binned sequences within
each subsystem class (Table 3).
Discussion
With increasing pressures to reduce or eliminate the use of
antimicrobials in production animals, there is a growing need to
better understand the effects elicited by these agents in order to
identify alternative approaches that might be used to maintain
animal health. Antibiotic usage at subtherapeutic levels is
postulated to result in modulations to the microbes within the
gut, resulting in the suppression of bacterial pathogens, reduction
of nutrient use by the microflora, increased production of vitamins
and other nutrients by the microflora, and reduced production of
Figure 2. Bacterial class distributions among the three timepoints after the start of treatments, using V3 amplicon sequencing
(n=89,652). For each timepoint, C = control diet, M = monensin treatment, V = monensin/virginiamycin treatment, and T = monensin/tylosin
treatment.
doi:10.1371/journal.pone.0027949.g002
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monensin/AGP regimen typical of that applied to broilers.
Treatment with monensin alone acted to affect a number of
bacterial genera within the chicken cecum. Monensin acted to
significantly deplete sequences classified as Roseburia, an effect that
was also observed in the monensin/AGP treatment groups. One of
the depleted OTUs classified as Roseburia was by far the most
abundant OTU identified, representing 19.1% of all binned
sequences. Roseburia is known as a butyrate-producing organism,
belonging to the Lachnospiraceae family, with a high capacity to form
conjugated linoleic acid from linoleic acid [28,29,30]. Conjugated
linoleic acid has been shown to exhibit anti-obesetic and anti-
diabetogenic properties [28]. Recently, Roseburia was shown to be
negatively correlated with mouse obesity; that is, Roseburia spp.
were restored in the cecal contents of mice treated to revert from
an obese to non-obese state [28]. In other studies, this genus has
also been identified as a key player in dietary changes related to an
obese versus non-obese state [31,32] and has been negatively
correlated with growth performance in production pigs [33].
While this evidence is circumstantial, it is possible that a reduction
in Roseburia could promote weight gain in birds or more simply
serve as an indicator of growth-promoting effects on the gut
microbial level.
In contrast to the Roseburia depletions, monensin and monensin/
AGP treatment significantly enriched five OTUs at most time-
points that were classified as Coprococcus, which is also a butyrate-
producing member of the Lachnospiraceae family [34]. The exact
reasons for a depletion of Roseburia and a corresponding increase in
Coprococcus are unclear, but could represent the occupation of an
available niche within the gut resulting in an overall balance of
Firmicutes belonging to the Lachnospiraceae family. Another abundant
OTU identified as enriched by monensin and monensin/AGP
treatments was classified as the genus Anaerofilum. Anaerofilum is a
genus of the Ruminococcaceae family containing strictly anaerobic,
gram-positive bacteria [35] but is poorly described in the
literature. Therefore, it is difficult to gauge the possible impact
that the enrichment of this OTU might have in the chicken cecum
microbial community.
Monensin treatment alone acted to significantly deplete the
most abundant Lactobacillus OTU, representing 3.2% of the total
binned sequences. Previous work has demonstrated that the use of
growth promoters and additive dietary enzymes act to reduce
lactobacilli populations in the ileum and cecum [36,37] as does the
use of monensin [38]. In addition to the Lactobacillus OTUs, an
abundant OTU classified as Enterococcus was also depleted in
response to monensin, monensin/virginiamycin, and monensin/
tylosin treatments. In a controlled experiment such as that
performed here, this might be expected because enterococci can
be susceptible to ionophores, virginiamycin, and tylosin. However,
in poultry production environment utilizing growth promoters,
multidrug resistant enterococci are common [39,40], so these
results might not be extended to the use of AGPs in production
settings. It has been shown, though, that Enterococcus resistance to
virginiamycin is not affected by the use of subtherapeutic levels of
the drug in feed, so it is unclear if these levels would actually drive
the persistence of resistant enterococci clones [41,42].
Figure 3. Bacterial family distribution within the Firmicutes phylum at the three timepoints after the start of treatment using V3
amplicon sequencing (n=53,588). For each timepoint, C = control diet, M = monensin treatment, V = monensin/virginiamycin treatment, and
T = monensin/tylosin treatment.
doi:10.1371/journal.pone.0027949.g003
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from determining the precise effects of growth promoters alone,
some changes in the microbiome were observed in the monensin/
AGP treatment groups that were not seen in the monensin-alone
treatment group. The most apparent of these changes were
significant enrichments in sequences classified as E. coli. Previous
culture-dependent studies have not observed an effect on E. coli
populations in response to growth promoters [43]. However, the
growth promoters used should not have a spectrum of activity that
includes E. coli, so this was not necessarily a surprising finding.
Some other abundant OTUs were identified as unique to the
monensin/virginiamycin and monensin/tylosin treatment groups
as compared to the monensin and control groups at day 14 post-
treatment start. These included the genera Anaerotruncus and
Subdoligranulum, which are gram-positive, anaerobic non-spore-
forming bacteria [44,45], and Sedimentibacter, which is a spore-
forming, gram-positive anaerobe [46]. Subdoligranulum spp. have
been shown to be enriched under fructo-oligosaccharide treatment
in piglets [47] and have been associated with ‘‘healthy-specific’’
bacterial sequences identified in humans in a study of Crohn’s
disease [48]. The implications of these unique microbes in growth-
promoting microbial health are unclear, however they could
potentially be used as markers of a healthy gut state. Overall, a
number of bacterial taxa were modulated through the use of
monensin/virginiamycin and monensin/tylosin, but the cause and
effect relationships driving these shifts remain to be determined.
At all timepoints and treatment groups, Firmicutes was the
predominant phylum identified within the chicken cecum, similar
to what has been previously described [49,50]. Few studies have
previously examined the longitudinal succession of microbes in the
chicken GI tract. A study by Lu et al. examined the succession of
microbes in the ileum and cecum of chickens fed diets devoid of
any coccidiostat or growth promoting agent [49]. They found that
Firmicutes dominated the chicken cecum throughout the grow-out
phase of the bird, and a large proportion of the Firmicutes they
identified belonged to the Clostridium genus (29–46%) with few or
no identified Proteobacteria. The chickens assessed in our study
generally lacked Clostridium, and were instead predominated by
sequences belonging to the Lachnospiraceae, Ruminococcaceae, and
Incertae Sedis IV families. Many factors could contribute to these
differences, including different diets, bird type, environment, and
rearing, as well as differences in technical methodologies. These
complexities make it difficult and unjustified to compare with
other studies in this manner. Evident from this work, though, is
that bird age and gut maturation had a much greater effect on
microbiome than did treatment effects. We observed an increase
in the complexity of the chicken cecum microbiome over time,
with a shift from apparently transient to stable populations, similar
to previous work [49]. The clustering approach further clarified
the diversification of the chicken cecum of the aging bird, with
more OTUs emerging over time than those disappearing. The
cecum microbiome at days 14, 21, and 42 of age were
considerably more complex than day 7 birds (Table 1 and
Fig. 8), underscoring the finding that the chicken cecum is
simplified but transient in the young bird. Also, it was evident that
changes occurred with respect to bacterial clones classified within
Figure 4. Rarefaction curves of samples from the different groups examined in this study using a cutoff value of 0.03. For each
timepoint (D0, D7, D14, and D35), C = control diet, M = monensin treatment, V = monensin/virginiamycin treatment, and T = monensin/tylosin
treatment.
doi:10.1371/journal.pone.0027949.g004
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others classified within the same genus. Overall, OTU analysis
showed that the effects of monensin/AGP treatment were subtle
compared to gut maturation effects. However, the greatest effects
of our monensin/AGP treatments were observed at 14 days after
the start of treatment, and monensin/virginiamycin and monen-
sin/tylosin treatment appeared to modulate the cecal microbiome
towards a more mature state with microbiome compositions more
closely resembling later age timepoints.
It has previously been suggested that the ‘‘core’’ microbiome in
the gut is not dictated by the actual bacterial species present, but
by the collective functional traits that this community contains
[49]. The results of this study support the concept that ‘‘what
they are doing,’’ not ‘‘who is there,’’ likely best defines the core
gut microbiome. We observed no differences in the chicken
cecum communities in response to age or anticoccidial and
growth promoter treatments when analyzed on the broadest
functional classifications. However, significant differences were
detected using the most focused subsystem classifications. The
functional groups that were identified as significantly enriched in
the metagenomes of monensin/virginiamycin and monensin/
tylosin treatment groups, but not in the monensin-treated groups,
included IncF and IncI1 type IV conjugative secretion systems,
type I fimbrial systems, and transporter systems. IncI1 and IncF
plasmid types are most common among E. coli; thus the increase
in gene sequences encoding these type IV secretion systems is
likely an effect of E. coli enrichment [51,52]. Similarly, the
enrichment of type I fimbrial sequences is likely attributed to the
increase in E. coli populations. In contrast, the ‘transporters in
models’ subsystem that was significantly enriched by monensin/
virginiamycin and monensin/tylosin treatment contained se-
quences with BLAST similarity across many taxa. The predicted
proteins of this group had various biological processes, including
the transport of amino acids, iron and manganese, potassium and
sodium, sugars, heavy metals, and calcium. Modification of the
availability of transport systems in a microbial community might
improve the range of carbon sources available for utilization,
increase metabolic precursor availability for the synthesis of
amino acids and metabolic intermediates, increase the efficiency
in sugar mixture utilization through catabolic repression, and
control overflow metabolism resulting in reduced acetate
production [53].
The spectrums of activity of virginiamycin and tylosin are
somewhat similar. Virginiamycin is a streptogramin with a
narrow spectrum of activity that includes gram-positive bacteria
(i.e., staphylococci, streptococci, and enterococci) and some
gram-negative cocci [26]. Genes associated with virginiamycin
resistance include vat(A–E), vgb(A), vga(A), and mrs(A)[ 2 6 ] .
Figure 5. Most abundant OTUs identified in chicken cecum samples throughout all timepoints. Classifications of representative
sequences from the OTU using RDP with their bootstrap confidence values are shown, as well as if an OTU was significantly enriched (green) or
depleted (red) compared to the control group for that timepoint (p,0.05). For each timepoint (D7, D14, and D35), C = control diet, M = monensin
treatment, V = monensin/virginiamycin treatment, and T = monensin/tylosin treatment.
doi:10.1371/journal.pone.0027949.g005
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27949Figure 6. Dendrogram depicting relationships among the experimental groups in this study using OTU analysis, generated using
Bray-Curtis index. Circled clusters represent arbitrary groupings showing the groups that are most similar to one another. For each timepoint (D0,
D7, D14, and D35), C = control diet, M = monensin treatment, V = monensin/virginiamycin treatment, and T = monensin/tylosin treatment.
doi:10.1371/journal.pone.0027949.g006
Figure 7. Venn diagram illustrating shared and unique OTUs at day 14 days after the start of treatments. Numbers below groups
indicate the number of OTUs within each sector. For each timepoint, C = control diet, M = monensin treatment, V = monensin/virginiamycin
treatment, and T = monensin/tylosin treatment.
doi:10.1371/journal.pone.0027949.g007
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PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27949Figure 8. Hierarchical clustering of OTU similarity and group similarity using normalized abundances. Key genera are highlighted to
the right of each cluster. For each timepoint (D0, D7, D14, and D35), C = control diet, M = monensin treatment, V = monensin/virginiamycin
treatment, and T = monensin/tylosin treatment.
doi:10.1371/journal.pone.0027949.g008
Table 2. Summary of shotgun metagenome sequencing of chicken cecum samples.
Day 14
control
Day 14
monensin
Day 14
monensin
+ tylosin
Day 14 monensin
+ virginiamycin
Day 35
control
Day 35
monensin
Day 35
monensin
+ tylosin
Day 35 monensin
+ virginiamycin
Number of reads 128,982 305,528 115,681 182,848 156,320 163,732 121,864 116,264
Total size (bp) 32,338,847 79,616,004 27,138,472 71,548,774 62,175,491 65,442,527 47,477,308 45,454,330
Average read length 250.72 260.58 234.6 391.3 397.7 399.7 389.6 390.9
Plasmids (%) 0 0 0.1 0.1 0 0 0.1 0
Eukaryota (%) 2.1 3.4 1.4 2.2 0.5 0.5 0.7 0.6
Bacteria (%) 95.6 94.2 96.1 95.4 97.1 97.2 96.8 96.9
Viruses (%) 0.2 0.2 0.4 0.3 0.3 0.3 0.3 0.3
Archaea (%) 2.1 2.1 1.9 2.1 2.1 2 2.1 2.2
doi:10.1371/journal.pone.0027949.t002
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PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27949Tylosin is a macrolide-class antibiotic with broad-spectrum
activity against gram-positive bacteria and a limited spectrum
of activity against gram-negative bacteria. Genes associated
with macrolide resistance include the erm genes encoding
ribosomal methylases, the mef and msr genes encoding for
efflux proteins [27]. We searched our metagenomic datsets for
these virginiamycin and tylosin resistance genes, and they were
present in all treatments and timepoints examined but did not
differ significantly in their distribution between groups.
Furthermore, analysis of the shotgun metagenomic dataset for
all antibiotic resistance-associated subsystems detected no
significant differences in the distribution of these subsystems
among the control versus treatment groups, suggesting that
subtherapeutic treatment with virginiamycin and tylosin did
not enrich for resistance-associated genes in these short-term
controlled experiments (Table 3). This finding may not be
extendable to the commercial poultry environment, though,
since different sources of microbes and differences in selective
pressures in these environments could contribute to the
emergence of drug resistant microorganisms.
Overall, this study identified a number of significant
modulations within the chicken cecum in response to monensin
alone, monensin/virginiamycin, and monensin/tylosin treat-
ment. Some of these identified changes might help to explain
why the use of growth promoters and anticoccidials results in
improved health and weight gain. However, these identified
changes are descriptive in nature, therefore it is unclear if the
modulated bacteria are playing a role in the benefits conferred
through gut microbial modulation, if they are artifacts, or if they
are markers of a modulated gut that confers health benefits to
Figure 9. Comparison of functional group distribution identified via shotgun metagenomic sequencing at timepoints D14 and D35.
Only groups with multiple significant shifts (p,0.05) are shown, from a total of 773 functional subsystems. Functional groups that were significantly
enriched (green) or depleted (red) compared to the control group for that timepoint are shown (p,0.05). For each timepoint (D0, D7, D14, and D35),
C = control diet, M = monensin treatment, V = monensin/virginiamycin treatment, and T = monensin/tylosin treatment.
doi:10.1371/journal.pone.0027949.g009
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PLoS ONE | www.plosone.org 11 November 2011 | Volume 6 | Issue 11 | e27949the host. A limitation to this study is that it was performed only
in the chicken cecum. Future work should also include locations
in the upper GI tract to determine the modulations that occur
there, since they are also likely important in the overall health of
the avian GI tract. Also, this study was performed in a controlled
animal facility experiment, thus the microbes encountered in this
environment are likely much different than those encountered in
poultry production. Finally, samples from multiple animals and
experiments were pooled, negating the ability to assess animal-
to-animal and experiment-to-experiment variation. However,
recent high throughput sequencing of commercial pigs revealed
that the fecal microbiota of individual pigs within the same farm
converges over time, suggesting that animal-to-animal variation
could be minimal in genetically similar production animals, and
that environment plays a larger role in determining the fate of
the production animal gut microbiome [54]. Nevertheless, this
study provides a more comprehensive glimpse at the gut
microbial modulations in response to growth promoters in
poultry, and provides future targets and markers with which to
mimic the effects of growth promoters using alternative
approaches.
Supporting Information
Figure S1 Analysis of bacterial taxa within each group
and timepoint using the RDP Database. For each time-
point, taxa that are significantly enriched (green) or depleted (red)
compared to control groups are depicted (p,0.05). For each
timepoint, C = control diet, M = monensin treatment, V =
monensin/virginiamycin treatment, and T = monensin/tylosin
treatment.
(TIF)
Figure S2 PCoA plot of similarities between the differ-
ent timepoints and treatments examined. For each time-
point, C = control diet, M = monensin treatment, V =
monensin/virginiamycin treatment, and T = monensin/tylosin
treatment.
(TIF)
Table 3. Summary of resistance-associated subsystems among shotgun metagenomic reads.
Class D14C
A D14M D14V D14T D35C D35M D35V D35T
Multidrug resistance efflux pumps 1948 1972 2042 1817 2103 1955 2141 1995
Fluoroquinolone resistance 545 496 435 516 425 459 377 395
Cobalt-zinc-cadmium resistance 287 358 427 271 391 427 382 362
Tetracycline resistance, ribosome protection 224 267 269 261 253 242 256 250
Beta-lactam resistance 120 148 131 127 119 176 99 155
Vancomycin resistance 113 121 107 106 114 107 122 117
Vancomycin tolerance in Streptococcus pneumoniae 59 52 71 20 117 73 104 94
Acriflavin resistance 47 53 61 43 58 138 48 61
Streptothricin resistance 36 37 45 38 24 17 25 27
Integrons 27 22 36 28 29 46 33 29
Methicillin resistance in Staphylococcus 27 22 19 20 27 26 10 19
Multidrug resistance, tripartite systems in Gram-negative
bacteria
20 16 30 28 8 33 20 27
Arsenic resistance 16 9 19 18 15 19 10 5
Multidrug resistance, 2-protein systems in Gram-positive
bacteria
16 24 30 8 42 22 15 24
Multidrug resistance (MdtABCD) 16 11 20 20 6 5 12 14
Colicin E2 tolerance 14 15 31 10 10 17 23 21
USS-DB-2 11 5 15 8 4 5 10 8
Aminoglycoside resistance 7 8 20 10 7 5 5 5
Multiple antibiotic resistance Mar locus 7 5 12 5 6 6 8 8
Zinc resistance 7 21 12 25 18 45 30 24
Multidrug efflux pump in Campylobacter jejuni (CmeABC) 5 1 12 0 6 4 2 3
USS-DB-1 5 13 5 15 12 14 18 10
Mercuric reductase 2 2 3 5 1 2 7 2
Mercury resistance 0 0 1 5 0 0 2 2
MexA-MexB-OprM multidrug efflux 0 0 0 0 0 0 3 0
Teicoplanin resistance in Staphylococcus 0 0131003
U S S - D B - 6 0 1000020
Raw counts were normalized to day 14 monensin group total read counts.
AD14C = Day 14 control; D14M = Day 14 monensin; D14V = day 14 monensin + virginiamycin; D14T = D14 monensin + tylosin; D35C = Day 35 control; D35M = Day
35 monensin; D35V = day 35 monensin + virginiamycin; D35T = 35 monensin + tylosin.
doi:10.1371/journal.pone.0027949.t003
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PLoS ONE | www.plosone.org 12 November 2011 | Volume 6 | Issue 11 | e27949Figure S3 Distribution of functional groups from shot-
gun metagenome sequencing, using the broadest func-
tional subsystem classification in MG-RAST (n=29). For
each timepoint, C = control diet, M = monensin treatment, V =
monensin/virginiamycin treatment, and T = monensin/tylosin
treatment.
(TIF)
Figure S4 Breakdown of functional group distributions
at D14C using subsystem analysis in MG-RAST. All other
timepoints and treatments were similar in their distributions.
(TIF)
Figure S5 Two-way hierarchical clustering of 773
functional group subsystems identified using MG-RAST,
based upon normalized abundances. For each timepoint
(Day 14 and Day 35), C = control diet, M = monensin
treatment, V = monensin/virginiamycin treatment, and T =
monensin/tylosin treatment.
(TIF)
Table S1 Bacterial phyla distributions (%) at the three
timepoints after the start of treatments. For each timepoint,
C = control diet, M = monensin treatment, V = monensin/
virginiamycin treatment, and T = monensin/tylosin treatment.
(XLSX)
Table S2 Most abundant OTUs with significant changes
in response to anticoccidial/growth promoter treat-
ment. See Fig. 5 for description of table.
(XLSX)
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